BRKR
NASDAQBruker Corporation
SectorIndustrialsIndustryBiotechnology: Laboratory Analytical Instruments
Price$57.28-0.95 (-1.62%)
01:30 PM07:45 PM
News · 26 weeks70+25%
2025-12-142026-06-07
Mix3390d
- Other14(42%)
- SEC Filings10(30%)
- Insider5(15%)
- Earnings2(6%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- PRBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026At ASM Microbe 2026, Bruker Corporation's (NASDAQ:BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604057503/en/MALDI Biotyper® sirius CA System, delivering high‑throughput microbial identification to support efficient clinical laboratory workflows and improved diagnostic turnaround times During the ASM 2026 meeting, Bruker showcases the expa
- PRBruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy IndustryAt ASMS, Bruker Corporation (NASDAQ:BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this with unparalleled mass resolution (>10M) and sub-parts-per-million mass accuracy, plus isotope fine structure identification-confirmation, which enables the most confident identification of molecular species in ultra-complex mixture
- ANALYSTWolfe Research resumed coverage on BrukerWolfe Research resumed coverage of Bruker with a rating of Peer Perform
- PRBruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease BiologyBruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing Launch of eXtreme 10M resolution novel timsMRMS™ mass spectrometer for ultra-complex mixture analysis in energy industry and life-science research Breakthrough timsUltra™ AIP bottom-up proteomics performance: instrument improvements, new razor-PASEF™ methods and Spectronaut 21 software enable ID and LFQ beyond 10,000 proteins in cell lines and tissue, with >6,500 proteins at 500 SPD, and leading plasma proteomics performance with single-particle P2 enrichment Revolutionary timsOmni™ enables unmatched multi-stage, ultra-sensitive trapped Ex
- SECSEC Form SD filed by Bruker CorporationSD - BRUKER CORP (0001109354) (Filer)
- SECAmendment: Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K/A - BRUKER CORP (0001109354) (Filer)
- PRChampalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRIWorld's highest-field MRI system provides leading disease biology research capabilities Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical. This press release features multimedia. View the full release here: https://www.b
- SECBruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BRUKER CORP (0001109354) (Filer)
- INSIDERDirector Bernard Thierry was granted 2,886 shares (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $87,800 worth of shares (2,000 units at $43.90) as part of a pre-agreed trading plan (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- SECBruker Corporation filed SEC Form 8-K: Other Events8-K - BRUKER CORP (0001109354) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bruker CorporationSCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)
- SECSEC Form 10-Q filed by Bruker Corporation10-Q - BRUKER CORP (0001109354) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bruker CorporationSCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)
- SECBruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BRUKER CORP (0001109354) (Filer)
- PRBruker Reports First Quarter 2026 Financial ResultsQ1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically Q1-26 GAAP diluted earnings per share (EPS) $0.02; non-GAAP diluted EPS $0.31 Q1-26 Bruker Scientific Instruments (BSI) bookings up high-single digits % organically yoy; BSI book-to-bill ratio above 1.0x for 3rd consecutive quarter Reconfirming previous FY2026 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President and C
- SECBruker Corporation filed SEC Form 8-K: Other Events8-K - BRUKER CORP (0001109354) (Filer)
- PRBruker Announces Date and Time of First Quarter 2026 Earnings Release and WebcastBruker Corporation (NASDAQ:BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q1 2026 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-4
- PRBruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026Bruker Spatial Biology features new GeoMx-to-CellScape and CellScape-to-CosMx cross-platform workflows and first-of-its-kind 208-plex CellScape XR spatial proteomics datasets Bruker Corporation (NASDAQ:BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417773444/en/PaintScape in sit
- PRBruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division ((Bruker Corporation, NASDAQ:BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius® system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO® automates the entire workflow - from patient sample to diagnostic result - e
- PRBruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak ManagementMALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target plates MALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria MALDI Biotyper®: Early KOL access to a novel cloud‑based identification solution, enabling identification against several specialist, expert‑curated libraries MALDI Biotyper®: Ongoing broad, multi‑year clinical and translational study programs advancing automation, potential future claims, and next‑generation analytics, including: IVDR-compliant clinical validation studies evaluating automated sample preparation workflows, cove
- INSIDERSEC Form 4 filed by Munch Mark4 - BRUKER CORP (0001109354) (Issuer)
- PRBruker Unveils New NMR Products and Workflow Solutions at ENC 2026Introductions span console electronics, quantitative NMR software, 80 MHz benchtop FT‑NMR, solid‑state and dissolution DNP, and automated protein and RNA workflows. At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (NASDAQ:BRKR) today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR. The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and dissolution Dynamic Nuclear Polarization (DNP), and digital workflows that support reproducible, unattended, and data-driven automation. This press release features multimedia. View t
- SECSEC Form DEFA14A filed by Bruker CorporationDEFA14A - BRUKER CORP (0001109354) (Filer)
- SECSEC Form DEF 14A filed by Bruker CorporationDEF 14A - BRUKER CORP (0001109354) (Filer)
BRKR FAQ
7 questionsWhat does Bruker Corporation do?
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy...Where does BRKR stock trade?
Bruker Corporation (BRKR) is listed on NASDAQ.What sector and industry is BRKR in?
Bruker Corporation operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.Does BRKR pay a dividend?
Yes. BRKR's next ex-dividend date is 2026-06-22 with a declared cash dividend of $0.05 per share, payable 2026-07-07.What are analysts saying about BRKR?
Bruker Corporation has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-06-02. Recent price targets cluster around $4000.00.What companies are similar to BRKR?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare BRKR side-by-side with any of them on Quantisnow.How can I track BRKR on Quantisnow?
Quantisnow aggregates Bruker Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRKR to receive live email and push alerts on every new disclosure.